From: Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
TP53/CHEK2status
Wild-type
Mutated
Progressive disease
A
B
Responders
C
D